RJ

Rutuben Jigarkumar Sonpura

Active Director Designated Partner DIN 11679070
DIN 11679070 First appointment Apr 2026
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Rutuben Jigarkumar Sonpura

Data last updated:

Rutuben Jigarkumar Sonpura is a Designated Partner at Shiv Pharmaceuticals Llp (since 2026).

DIN 11679070
Primary Designation Designated Partner
First Appointment 22 Apr 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner22 Apr 20262026Active

Board colleagues of Rutuben Jigarkumar Sonpura

NameDINCompanyDesignation
Anjanaben Bhupendrakumar Thakkar11679068Shiv Pharmaceuticals LlpDesignated Partner
Vinaben Pravinbhai Thakkar11679069Shiv Pharmaceuticals LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Shiv Pharmaceuticals Llp
Premium access

Shareholding and investment profile for Rutuben Jigarkumar Sonpura

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rutuben Jigarkumar Sonpura

Rutuben Jigarkumar Sonpura currently holds 1 directorship: Shiv Pharmaceuticals Llp (Designated Partner, since 22 Apr 2026).

Rutuben Jigarkumar Sonpura was first appointed on 22 Apr 2026 as Designated Partner at Shiv Pharmaceuticals Llp.

The current boards of Rutuben Jigarkumar Sonpura's companies include Anjanaben Bhupendrakumar Thakkar (Shiv Pharmaceuticals Llp), Vinaben Pravinbhai Thakkar (Shiv Pharmaceuticals Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available